Business
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"text","content":"`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety data on sixteen patients enrolled in open-label Phase 2 IgA nephropathy trial also to be presented at the World Congress of Nephrology Company to continue to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Conference call today at 4:30 PM ET IRVINE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its fourth quarter and full-year 2022 operating and financial results and reviewed recent business highlights. “Eledon began the year with a strategic decision to focus our financial and organizational resources on our kidney transplantation programs,” said David-Alexandre C. Gros, M.D., Chief Executive Officer. “Our decision was based on the significant unmet need to improve long term graft function and survival in kidney transplant, and the substantial existing data from both our anti-CD40 Ligand and historical anti-CD40 Ligands demonstrating their potential in pre-clinical models of organ transplantation. We are highly encouraged by the initial results to date from our ongoing Phase 1b trial evaluating tegoprubart in kidney transplantation, as well as the supportive safety data from our ALS and IgAN trials, and we look forward to sharing our kidney transplant data at the World Congress of Nephrology.” Fourth Quarter 2022 and Recent Corporate Developments Dosed fourth subject in a Phase 1b, open-label study to evaluate tegoprubart for the prevention of rejection in patients receiving a kidney transplant. The study has open sites in Canada, the United Kingdom and Australia. Eledon will share safety and efficacy results from the first three participants at the WCN, taking place March 30 – April 2, 2023 in Bangkok, Thailand.Strategically refocused the tegoprubart pipeline on the advancement of the Company’s kidney transplantation program. Eledon deprioritized the clinical development of tegoprubart in IgA Nephropathy (IgAN) and discontinued its Phase 1/2 trial for islet cell transplantation. The Company will share safety data from the Phase 2a IgAN study at the upcoming WCN meeting.Announced a collaboration with eGenesis for the use of te...